TABLE 2.
Dose at last visit among all patients, at data cutoff for patients continuing cenobamate, and at start of drug taper for patients discontinuing cenobamate
| All cenobamate, N = 240, n (%) a | Continuing cenobamate at data cutoff, N = 177, n (%) | Patients who discontinued cenobamate, N = 63, n (%) | |
|---|---|---|---|
| 12.5 mg/day | 2 (0.8) | 0 (0) | 2 (3.2) |
| 25 mg/day | 6 (2.5) | 0 (0) | 6 (9.5) |
| 50 mg/day | 11 (4.6) | 2 (1.1) | 9 (14.3) |
| 100 mg/day | 9 (3.8) | 6 (3.4) | 3 (4.8) |
| 150 mg/day | 17 (7.1) | 13 (7.3) | 4 (6.3) |
| 200 mg/day | 55 (22.9) | 41 (23.2) | 14 (22.2) |
| 250 mg/day | 23 (9.6) | 16 (9.0) | 7 (11.1) |
| 300 mg/day | 31 (12.9) | 28 (15.8) | 3 (4.8) |
| 350 mg/day | 23 (9.6) | 19 (10.7) | 4 (6.3) |
| 400 mg/day | 63 (26.3) | 52 (29.4) | 11 (17.5) |
a
For all cenobamate patients (N = 240), dose at the last visit did not include visits for drug taper/discontinuation.